1 |
CUI Z, ZHAO M H. Advances in human antiglomerular basement membrane disease[J]. Nat. Rev. Nephrol., 2011, 7(12): 697-705.
|
2 |
PEDCHENKO V, BONDAR O, FOGO A B, et al.. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis[J]. N. Engl. J. Med., 2010, 363(4): 343-354.
|
3 |
HELLMARK T, SEGELMARK M, UNGER C, et al.. Identification of a clinically relevant immunodominant region of collagen Ⅳ in Goodpasture disease[J]. Kidney Int., 1999, 55(3): 936-944.
|
4 |
HU S Y, JIA X Y, GU Q H, et al.. T cell responses to peptides of Goodpasture autoantigen in patients with anti-glomerular basement membrane disease[J]. Nephrology (Carlton), 2018, 23(4): 345-350.
|
5 |
OOI J D, PETERSEN J, TAN Y H, et al.. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells[J]. Nature, 2017, 545(7653): 243-247.
|
6 |
JIA X Y, CUI Z, YANG R, et al.. Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury[J]. Clin. J. Am. Soc. Nephrol., 2012, 7(6): 926-933.
|
7 |
CAIRNS L S, PHELPS R G, BOWIE L, et al.. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type Ⅳ collagen in Goodpasture's disease[J]. J. Am. Soc. Nephrol., 2003, 14(11): 2801-2812.
|
8 |
WU J, HICKS J, BORILLO J, et al.. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis[J]. J. Clin. Invest., 2002, 109(4): 517-524.
|
9 |
李耿,刘晓志,王志明,等. 双特异性抗体药物应用进展[J]. 生物技术进展, 2015, 5(06): 420-424.
|
10 |
MCADOO S P, REYNOLDS J, BHANGAL G, et al.. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN[J]. J. Am. Soc. Nephrol., 2014, 25(10): 2291-2302.
|
11 |
IYODA M, SHIBATA T, WADA Y, et al.. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis[J]. Nephrol. Dial. Transplant., 2013, 28(3): 576-584.
|
12 |
REYNOLDS J, PRESTON G A, PRESSLER B M, et al.. Autoimmunity to the alpha 3 chain of type Ⅳ collagen in glomerulonephritis is triggered by 'autoantigen complementarity'[J]. J. Autoimmun., 2015, 59: 8-18.
|
13 |
REYNOLDS J, MOSS J, DUDA M A, et al.. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease[J]. J. Pathol., 2003, 200(1): 118-129.
|
14 |
CANNEY M, O'HARA P V, MCEVOY C M, et al.. Spatial and temporal clustering of anti-glomerular basement membrane disease[J]. Clin. J. Am. Soc. Nephrol., 2016, 11(8): 1392-1399.
|
15 |
MCADOO S P, PUSEY C D. Anti-glomerular basement membrane disease[J]. Clin. J. Am. Soc. Nephrol., 2017, 12(7): 1162-1172.
|
16 |
REYNOLDS J, COOK P R, BEHMOARAS J, et al.. Genetic susceptibility to experimental autoimmune glomerulonephritis in the Wistar Kyoto rat[J]. Am. J. Pathol., 2012, 180(5): 1843-1851.
|
17 |
SADO Y, BOUTAUD A, KAGAWA M, et al.. Induction of anti-GBM nephritis in rats by recombinant alpha 3(Ⅳ)NC1 and alpha 4(Ⅳ)NC1 of type Ⅳ collagen[J]. Kidney Int., 1998, 53(3): 664-671.
|
18 |
ABBATE M, KALLURI R, CORNA D, et al.. Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type Ⅳ collagen[J]. Kidney Int., 1998, 54(5): 1550-1561.
|
19 |
ROBERTSON J, WU J, ARENDS J, et al.. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis[J]. Kidney Int., 2005, 68(3): 1061-1070.
|
20 |
WU J, BORILLO J, GLASS W F, et al.. T-cell epitope of alpha3 chain of type Ⅳ collagen induces severe glomerulonephritis[J]. Kidney Int., 2003, 64(4): 1292-1301.
|
21 |
WU J, HICKS J, OU C, et al.. Glomerulonephritis induced by recombinant collagen Ⅳ alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: a potential T cell-mediated mechanism[J]. J. Immunol., 2001, 167(4): 2388-2395.
|
22 |
YU X, PETERSEN F. A methodological review of induced animal models of autoimmune diseases[J]. Autoimmun. Rev., 2018, 17(5): 473-479.
|
23 |
HU S Y, GU Q H, WANG J, et al.. The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif[J]. J. Cell Mol. Med., 2017, 21(9): 2117-2128.
|
24 |
REYNOLDS J, NORGAN V A, BHAMBRA U, et al.. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis[J]. J. Am. Soc. Nephrol., 2002, 13(2): 359-369.
|